標題：奧樂妥珠單抗，Otlertuzumab，CAS: 1372645-37-8，AntibodySystem Laboratories

貨號：DHC85103

產(chǎn)品鏈接：http://www.atagenix.com/product_detail-75450.html

別名：TRU-016, CAS: 1372645-37-8

簡介：

奧樂妥珠單抗 Otlertuzumab (TRU-016) 是一種人源化抗 CD37 單克隆抗體，可用于癌癥研究。

貨號：DHC85103

產(chǎn)品品牌：Antibodysystem

通用名：Otlertuzumab

純度：>95% by SDS-PAGE.

濃度：1mg/ml

Formulationicon：0.01M PBS, pH 7.4.

內(nèi)毒素：Please contact with the lab for this information.

別名：TRU-016

靶點;物種：Human CD37

種類：Humanized

受體鑒定：VH-V-kappa-CH2-CH3

CAS: 1372645-37-8

存儲條件：

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

Store at +4°C short term (1-2 weeks).

Store at -20 °C 12 months.

Store at -80°C long term.

參考文獻：

Otlertuzumab more than a TRU(E) toddler in CLL? PMID: 24578490
Otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR(?) therapeutic protein, for relapsed or refractory NHL patients. PMID: 25146490
Randomized phase 2 study of otlertuzumab and bendamustine versus bendamustine in patients with relapsed chronic lymphocytic leukaemia. PMID: 27977057
Phase 1b study of otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR? therapeutic protein, in combination with rituximab and bendamustine in relapsed indolent lymphoma patients. PMID: 24927856
Anti-CD37 antibodies for chronic lymphocytic leukemia. PMID: 24555705
Emerging immunological drugs for chronic lymphocytic leukemia. PMID: 26153226
A phase 1 study evaluating the safety and tolerability of otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein in chronic lymphocytic leukemia. PMID: 24381226
Tumor lysis syndrome in the era of novel and targeted agents in patients with hematologic malignancies: a systematic review. PMID: 26758269
Anti-CD37 targeted immunotherapy of B-Cell malignancies. PMID: 30293139
Novel agents for chronic lymphocytic leukemia. PMID: 23680477
Refractory chronic lymphocytic leukemia--new therapeutic strategies. PMID: 21317446
New agents in chronic lymphocytic leukemia. PMID: 20425394
[Chemotherapy-free treatment of chronic lymphocytic leukemia?]. PMID: 24085367
Investigational therapies targeting CD37 for the treatment of B-cell lymphoid malignancies. PMID: 29323537
Emerging monoclonal antibodies and related agents for the treatment of chronic lymphocytic leukemia. PMID: 23252565
Current and emerging monoclonal antibody treatments for chronic lymphocytic leukemia: state of the art. PMID: 25249370
Gateways to clinical trials. PMID: 20383346
TRU-016, a humanized anti-CD37 IgG fusion protein for the potential treatment of B-cell malignancies. PMID: 19943209
Novel agents for the treatment of chronic lymphocytic leukemia. PMID: 21326166
Action of novel CD37 antibodies on chronic lymphocytic leukemia cells. PMID: 21886169
Tetraspanin CD37 directly mediates transduction of survival and apoptotic signals. PMID: 22624718
The use of monoclonal antibodies in the treatment of autoimmune complications of chronic lymphocytic leukemia. PMID: 23667725
Glycovariant anti-CD37 monospecific protein therapeutic exhibits enhanced effector cell-mediated cytotoxicity against chronic and acute B cell malignancies. PMID: 23883821
Pro-apoptotic effect of an anti-CD37 scFv-Fc fusion protein, in combination with the anti-CD20 antibody, ofatumumab, on tumour cells from B-cell malignancies. PMID: 25154027